Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Good morning, and we're continuing actually the presentations here at this year's Global Healthcare Conference. I'm Mani Foroohar, a senior analyst covering drug medicines here at SVB Leerink. I'm very fortunate to have Yvonne Greenstreet joining us from Alnylam. Yvonne, how are you doing today?
Yes. Good morning, everybody. Delighted to be here. We had a year of incredible performance at Alnylam in 2020. Commercial performance was great, delivered $306 million of global net product sales from ONPATTRO with 1,350 patients. And we're pleased with our innovative approaches to access. We've got 98% coverage of lives in the U.S.
GIVLAARI also did really well. First full year sales, $55 million, 200 patients. And again, great access, 94% in the U.S., but also sales in Germany, ATU in France and some other name patient sales
And OXLUMO was launched. It got approved in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
